<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of carotid artery stenting
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of carotid artery stenting
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of carotid artery stenting
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Jim, MD, MPHS, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Eidt, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph L Mills, Sr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The proximal internal carotid artery and the carotid bifurcation are the locations most frequently affected by carotid atherosclerosis. Progression of atherosclerotic plaque at the carotid bifurcation results in luminal narrowing, often accompanied by ulceration. This process can lead to cerebral ischemia (eg, transient ischemic attack, stroke) from arterial embolization, thrombosis, or less commonly from hemodynamic compromise. For patients with appropriate indications, options for carotid revascularization include carotid endarterectomy (CEA) or carotid angioplasty and stenting, which can be approached using several approaches, each with advantages and disadvantages.
        </p>
        <p>
         An overview of carotid artery stenting (CAS), including approaches to CAS and factors that may favor one approach over the other, and general issues surrounding periprocedural care are reviewed, including complications. CEA is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8193.html" rel="external">
          "Carotid endarterectomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H101619029">
         <span class="h1">
          CAROTID ATHEROSCLEROTIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of symptomatic or asymptomatic carotid atherosclerotic disease, including the indications for carotid revascularization and the choice between carotid endarterectomy [CEA] and CAS), is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3753902014">
         <span class="h2">
          Indications for stenting
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAS is an option for selected patients with contraindications to CEA due to high-risk anatomical or physiological factors for symptomatic (≥50 percent) or asymptomatic high-grade (≥80 percent) internal carotid artery stenosis. (See
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease", section on 'Carotid stenting'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease", section on 'Patients appropriate for CAS'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1536225174">
         <span class="h2">
          Risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the risk factors for a worse outcome identified for CAS, such as symptomatic carotid disease, increasing degrees of carotid stenosis, parallel those identified in major trials of CEA. (See
         <a class="medical medical_review" href="/z/d/html/8193.html" rel="external">
          "Carotid endarterectomy", section on 'Risk factors for poor outcome'
         </a>
         .)
        </p>
        <p>
         Other factors that may affect CAS outcomes in patients undergoing CAS include age, sex, composition and morphology of the stenotic lesion, and the presence of white matter lesions, among others.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – Data from the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial [
         <a href="#rid1">
          1
         </a>
         ], Carotid Revascularization Endarterectomy versus Stent trial (CREST) [
         <a href="#rid2">
          2-4
         </a>
         ], prospective series [
         <a href="#rid5">
          5-7
         </a>
         ], and retrospective reports [
         <a href="#rid8">
          8-10
         </a>
         ] suggest that patients ≥80 years old have a significantly higher risk of stroke and death at 30 days compared with younger patients following transfemoral CAS (TF-CAS). In addition, a retrospective study suggested that patients older than 80 had a higher incidence of unfavorable arterial factors that increased the technical difficulty of TF-CAS, such as aortic arch elongation, arch calcification, common carotid and innominate artery origin stenosis, common and internal carotid artery tortuosity, and a higher risk of residual stenosis post-stenting due to underlying vessel calcification [
         <a href="#rid11">
          11
         </a>
         ]. It is also postulated that older patients have a lower cerebral reserve that makes them more sensitive to minor cerebral emboli, which may be one factor explaining their higher risk of stroke during TF-CAS [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Age does not appear to have an appreciable effect on patient outcomes after transcarotid artery revascularization (TCAR), which combines the benefits of avoiding a potentially diseased aortic arch with a low rate of distal embolization. The higher complication rates associated with age seen in those undergoing TF-CAS have not manifested among those undergoing the TCAR procedure. In a study evaluating all patients undergoing carotid procedures in the Vascular Quality Initiative between 2015 and November 2018, 10,381 TF-CAS cases (from 269 centers) and 3152 TCAR cases (from 174 centers) were evaluated [
         <a href="#rid13">
          13
         </a>
         ]. The patients were divided into three different age groups: &lt;70 years, 71 to 79 years, and &gt;80 years. In-hospital mortality, stroke, myocardial infarction, and transient ischemic attack (TIA) were similar between the three age groups. TF-CAS was associated with an increased risk for stroke among older patients (&gt;77 years) but TCAR was not.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sex
         </strong>
         – Clinical studies indicate that the perioperative risk of CAS compared with CEA may be higher in females compared with males [
         <a href="#rid14">
          14-18
         </a>
         ]. Studies are conflicting whether the perioperative risk associated with CAS is more prevalent in symptomatic or asymptomatic women, although data favor increased risk in symptomatic females. Sex as it may impact the choice of CAS or CEA in symptomatic and asymptomatic individuals is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease", section on 'Factors influencing outcome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease", section on 'Factors influencing benefit and risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Composition and morphology of the stenotic lesion
         </strong>
         – For patients with atherosclerotic disease, heavily calcified carotid plaque [
         <a href="#rid19">
          19
         </a>
         ], ulcerated plaque [
         <a href="#rid6">
          6
         </a>
         ], increasing degree of carotid stenosis [
         <a href="#rid8">
          8
         </a>
         ], longer lesions, and presence of thrombus have been associated with an increased risk for stroke. Retrospective reviews also suggest that long carotid lesions (&gt;10 mm) [
         <a href="#rid8">
          8,20
         </a>
         ] or carotid segments with more than one lesion separated by normal vessel wall are associated with a higher stroke risk [
         <a href="#rid8">
          8
         </a>
         ]. An analysis of plaque characteristics derived from the CREST trial reported that only plaque length was associated with age with respect to stroke risk; however, it was responsible for only 8 percent of the excess stroke risk [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients with radiation-induced stenosis, a systematic review identified 27 studies including 533 patients who underwent CAS or CEA [
         <a href="#rid22">
          22
         </a>
         ]. For patients who underwent TF-CAS, the pooled estimate for any cerebrovascular adverse event was 3.9 percent, which was similar to that identified for CEA. However, the rate of restenosis (long-term) &gt;50 percent and/or occlusion was significantly higher in patients treated with CAS compared with CEA (22.5 versus 10.7 percent). An earlier meta-analysis that included 21 studies found similar results [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          White matter lesions
         </strong>
         – White matter lesions are likely a consequence of degenerative changes in the deep perforating arterioles. Risk factors for the development of white-matter lesions include age and hypertension. In the International Carotid Stenting Study (ICSS), the number of lesions identified on baseline brain imaging was correlated with stroke rates at 30 days [
         <a href="#rid24">
          24
         </a>
         ]. Patients who underwent CAS with ≥7 age-related white matter changes had a higher risk of stroke relative to those with &lt;7 lesions (hazard ratio [HR] 2.76, 95% CI 1.17-6.51) and relative to CEA (any stroke: HR 2.98, 95% CI 1.3-6.9; non-disabling stroke: HR 6.34, 95% CI 1.45-27.71). No differences in stroke rates were detected for those with &lt;7 lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other risk factors
         </strong>
         — Other medical risk factors associated with an increased risk for periprocedural complications (mainly stroke) and worse outcome after TF-CAS have been identified in uncontrolled prospective and retrospective studies. The assessment of medical risk prior to stenting and stroke risk associated with asymptomatic and symptomatic carotid stenosis are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other medical risk factors include [
         <a href="#rid6">
          6,20,25-30
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of aortic stenosis (may be an overall surrogate for atherosclerotic disease)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aortic arch calcification or variant aortic arch anatomy (transfemoral approach)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes mellitus with inadequate glycemic control (hemoglobin A1C &gt;7 percent)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptomatic compared with asymptomatic ipsilateral carotid stenosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemispheric TIA or minor stroke compared with retinal TIA or no symptoms
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic kidney disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oral anticoagulant therapy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emergency admission
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H312691643">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to CAS can be grouped into those that contraindicate the procedure, in general, and those that contraindicate a specific approach (TF-CAS, TCAR). General contraindications are listed below. These and other specific contraindications are discussed in topics that discuss a specific approach [
         <a href="#rid31">
          31
         </a>
         ] (see
         <a class="local">
          'Indications for stenting'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Contraindications for transfemoral approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Anatomic requirements and eligibility'
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H1933623147">
         <span class="h3">
          Absolute
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visible thrombus within the lesion detected on preoperative imaging (eg, ultrasound, angiography) or intraoperative imaging
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inability to gain vascular access
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active infection
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2685232747">
         <span class="h3">
          Relative
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, relative contraindications to CAS include the following. Additional considerations depend upon the approach to carotid stenting.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe plaque calcification, circumferential carotid plaque
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe carotid tortuosity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Near occlusion of the carotid artery  (
         <a class="graphic graphic_figure graphicRef129242" href="/z/d/graphic/129242.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid32">
          32,33
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small internal carotid artery (may not accommodate available commercial artery stents)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2997282035">
         <span class="h2">
          Timing and other considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The timing of intervention in patients with symptomatic carotid disease depends on the nature and severity of symptoms (eg, TIA, stroke) and is discussed separately. Although the periprocedural risks associated with CAS are similar to CEA performed earlier (0 to 7 days), the stroke risk for CAS may be slightly higher [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease", section on 'Timing of revascularization'
         </a>
         .)
        </p>
        <p>
         Other considerations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral carotid stenosis – For patients with severe bilateral carotid stenosis, we suggest a staged approach rather than simultaneous CAS [
         <a href="#rid8">
          8,36,37
         </a>
         ]. A staged approach limits the length of the procedure and intravenous contrast load, whereas simultaneous CAS theoretically increases the risk for cerebral hyperperfusion syndrome and the risk of severe bradycardia or hypotension related to bilateral baroreceptor irritation [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="local">
          'Hyperperfusion syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prophylactic carotid stenting – Given that prophylactic CEA prior to another surgical procedure is generally not supported by available evidence, it may not be reasonable to offer CAS in this setting. A decision to proceed should be individualized based upon the risk of perioperative stroke weighed against the risk of bleeding associated with ongoing antiplatelet therapy (eg,
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ), which is recommended following CAS. (See
         <a class="medical medical_review" href="/z/d/html/1097.html" rel="external">
          "Coronary artery bypass grafting in patients with cerebrovascular disease", section on 'Method of carotid revascularization'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8193.html" rel="external">
          "Carotid endarterectomy", section on 'Carotid endarterectomy prior to other procedures'
         </a>
         and
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1356847384">
         <span class="h1">
          APPROACH TO CAROTID ARTERY STENTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         As experience using stents to treat atherosclerotic lesions at other peripheral sites increased, CAS was developed with the aim of reducing the systemic (eg, myocardial infarction [MI]) and local risks (eg, nerve injury) associated with carotid endarterectomy (CEA), which has been the established as the gold standard for carotid revascularization for atherosclerotic disease. To provide a durable benefit, the periprocedural risk of stroke and death for any carotid revascularization must be ≤3 percent for asymptomatic patients and ≤6 percent for symptomatic stenosis. (See
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease"
         </a>
         .)
        </p>
        <p>
         With the introduction of CAS, some outcomes improved with CAS, but stroke rates were increased in early trials, likely related to certain aspects of the stent technology, the conduct, the procedure (eg, crossing a diseased aortic arch), and possibly the nature of cerebral protection. Improvements in stent devices, differing access approaches, and differing embolic protection methods (distal filter protection, proximal flow arrest, proximal flow reversal) have all been aimed at reducing the risk of stroke associated with CAS and stroke rates have improved for some, but not all patients. Alternative access approaches and technologic refinements continue.
        </p>
        <p>
         CAS can be performed percutaneously or through a small incision in the neck.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Percutaneous CAS obtains vascular access through the groin (transfemoral), axillary artery (transaxillary), brachial artery (transbrachial), radial artery (transradial) [
         <a href="#rid39">
          39-42
         </a>
         ], or direct puncture of the carotid (transcervical). By far the most common approach is via the right (or left) common femoral artery (ie, transfemoral CAS [TF-CAS]). Percutaneous approaches for CAS are typically performed in conjunction with a distal filter-type embolic protection device; proximal occlusion has also been used [
         <a href="#rid43">
          43-45
         </a>
         ]. (See
         <a class="local">
          'Transfemoral carotid revascularization'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transcarotid artery revascularization (TCAR) is a specific technique that accesses the carotid through a short incision at the base of the neck over the proximal ipsilateral common carotid artery [
         <a href="#rid43">
          43-61
         </a>
         ]. The TCAR procedure is performed through a short carotid sheath in conjunction with flow reversal for embolic protection using a proprietary device. (See
         <a class="local">
          'Transcarotid revascularization'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1259100468">
         <span class="h2">
          Transfemoral carotid revascularization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials have compared CEA with TF-CAS in patients with either symptomatic or asymptomatic carotid disease [
         <a href="#rid1">
          1,2,4,62-69
         </a>
         ]. No trials have compared CAS with medical therapy alone. Compared with CEA, the periprocedural risk for stroke, and possibly longer-term risk, following TF-CAS is higher [
         <a href="#rid70">
          70-72
         </a>
         ]. Combined 30-day stroke and death rates for TF-CAS in randomized trials range from 6 to 9 percent for symptomatic and from 2 to 4 percent for asymptomatic patients [
         <a href="#rid73">
          73-76
         </a>
         ]. Stroke rates have improved since the introduction of CAS, achieving long-term benefit for symptomatic and asymptomatic patients [
         <a href="#rid73">
          73-76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H242158886">
         <span class="h3">
          Clinical trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         A meta-analysis of 16 trials (including CREST [
         <a href="#rid2">
          2,4,68,69
         </a>
         ], ICSS [
         <a href="#rid66">
          66,67
         </a>
         ], Endarterectomy versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis [EVA-3S] [
         <a href="#rid63">
          63
         </a>
         ], Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy [SAPPHIRE] [
         <a href="#rid64">
          64,65
         </a>
         ], and others) compared endovascular treatment (mainly TF-CAS) with CEA [
         <a href="#rid74">
          74
         </a>
         ]. The risk of periprocedural stroke or death at 30 days was increased for CAS compared with CEA (8.2 versus 5.0 percent, odds ratio [OR] 1.72, 95% CI 1.29-2.31). In subgroup analysis, a higher risk of periprocedural stroke or death was seen for CAS patients ≥70 years of age compared with CEA (OR 2.20, 95% CI 1.47-3.29). By contrast, the risk of periprocedural stroke or death for patients &lt;70 years of age was similar for CAS and CEA (OR 1.16, 95% CI 0.80-1.67). CAS had a higher rate of death or stroke during the periprocedural period or ipsilateral stroke during follow-up (10.4 versus 7.7 percent, OR 1.39, 95% CI 1.10-1.75), but a lower risk for MI (OR 0.44), cranial nerve palsy (OR 0.08), and access site hematoma (OR 0.37). The randomized trials of carotid stenting in symptomatic and asymptomatic patients are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease", section on 'Carotid stenting'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1106.html" rel="external">
          "Management of symptomatic carotid atherosclerotic disease", section on 'Trials comparing CAS with CEA'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H728581876">
         <span class="h3">
          Registry data
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 30-day death and stroke rate was 3.6 percent in an analysis of two multicenter postmarket surveillance registries of CAS (EXACT, CAPTURE-2) that included 6320 high-risk patients [
         <a href="#rid77">
          77
         </a>
         ]. In the SAPPHIRE worldwide registry, which included 2001 patients followed for 30 days, mortality was 1.1 percent and stroke rate was 3.2 percent [
         <a href="#rid78">
          78
         </a>
         ]. A similar rate was found in later large reviews [
         <a href="#rid10">
          10,79-81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2531215230">
         <span class="h2">
          Transcarotid revascularization
         </span>
         <span class="headingEndMark">
          —
         </span>
         The available clinical data on the TCAR procedure consist of safety and efficacy studies, institutional reports, and real-world outcomes reported in the TCAR Surveillance Project (TSP). The updated Society for Vascular Surgery guidelines on the management of extracranial cerebrovascular disease note that TCAR procedure is at least equivalent to CEA, with some potential improvements, and compared with TF-CAS, the overall data demonstrate better outcomes [
         <a href="#rid82">
          82
         </a>
         ]. TCAR may be preferable to CEA and TF-CAS for high-risk patients (anatomic and physiologic) [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3243199837">
         <span class="h3">
          Safety and efficacy studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of the TCAR procedure with internal carotid flow reversal was first described in 2004 [
         <a href="#rid60">
          60,61
         </a>
         ]. However, the first report of TCAR performed with the neuroprotection system was published in 2011. The Silk Road Medical Embolic PROtectiOn System: First-In-Man (PROOF) study reported initial procedural success in 68 of 75 (91 percent) [
         <a href="#rid43">
          43
         </a>
         ]. There were three device malfunctions and four artery dissections with device insertion. Of note, 9 percent had transient intolerance to flow reversal, which was managed successfully by minimizing the duration of flow reversal. At 30 days, there were no major strokes, MIs, or deaths [
         <a href="#rid84">
          84
         </a>
         ]. In a subgroup of 31 patients who underwent a diffusion-weighted magnetic resonance imaging examination, 16 percent had evidence of new ischemic brain lesion without clinical sequelae.
        </p>
        <p>
         The Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure (ROADSTER) study was a prospective, single-arm, multicenter clinical trial that enrolled 208 patients considered at high risk for complications from CEA who had either symptomatic ≥50 percent stenosis or asymptomatic ≥70 percent stenosis [
         <a href="#rid85">
          85
         </a>
         ]. Between 2012 and 2014, 67 patients were enrolled as lead-in cases, and 141 were enrolled in the pivotal phase, and this latter group was evaluated for outcome analysis. The mean flow reversal time was 13 minutes, and there was one case (0.7 percent) of intolerance to high-flow reversal. The initial technical success rate was 99 percent and the all-stroke rate was 1.4 percent. The composite rate of stroke/death was 2.8 percent, and the composite rate of stroke/death/MI was 3.5 percent. One patient (0.7 percent) had postoperative hoarseness from potential 10th cranial nerve injury, which resolved at six months. In a follow-up study, 165 patients (112 of 141 pivotal ROADSTER patients as well as 53 of 78 extended-access patients) had outcomes analyzed at one year [
         <a href="#rid86">
          86
         </a>
         ]. Patients aged 75 years and older comprised 43.3 percent of the cohort; 79.9 percent were asymptomatic. In this group, the ipsilateral incidence of stroke incidence was 0.6 percent; seven patients (4.2 percent) died during follow-up, but none of the deaths were neurologic in origin.
        </p>
        <p>
         The ROADSTER 2 study was a prospective, single-arm, multicenter post-approval registry that enrolled 692 patients between 2015 and 2019. Patients were considered at high risk for complications from CEA with either symptomatic ≥50 percent stenosis or asymptomatic ≥80 percent stenosis. In the "per protocol" study population, which included 632 patients (ie, 60 protocol violations excluded), the primary endpoint of procedural success (ie, technical success plus absence of stroke/death/MI) was 97.9 percent [
         <a href="#rid87">
          87,88
         </a>
         ]. In the per protocol group, the perioperative (30-day) stroke rate was 0.6 percent, the composite rate of stroke/death was 0.8 percent, and composite rate of stroke/death/MI was 1.7 percent.
        </p>
        <p class="headingAnchor" id="H689269658">
         <span class="h3">
          Observational studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcomes for the TCAR procedure appear to be at least equivalent to CEA in database reviews [
         <a href="#rid89">
          89-93
         </a>
         ], and other observational studies [
         <a href="#rid94">
          94
         </a>
         ]. A multi-institutional analysis reviewed 663 patients undergoing TCAR or CEA [
         <a href="#rid94">
          94
         </a>
         ]. TCAR patients had higher prevalence of several comorbidities (diabetes, hyperlipidemia, coronary disease, and renal insufficiency). Overall stroke rates were similar at 30 days (1.0 percent TCAR versus 1.1 percent CEA) and one year (2.8 percent TCAR and 3.0 percent CEA) in the unmatched groups. After propensity matching based on preoperative comorbidities, 292 TCAR patients were compared with 292 CEA patients. Stroke (1.0 percent TCAR versus 0.3 percent CEA) and death (0.3 percent TCAR versus 0.7 percent CEA) were similar at 30 days and comparable at one year (stroke 2.8 percent TCAR versus 2.2 percent CEA; death 1.8 percent TCAR versus 4.5 percent CEA). The two groups had a similar composite endpoint of stroke/death/MI (2.1 percent TCAR versus 1.7 percent CEA), but TCAR was associated with a decreased rate of cranial nerve injury (0.3 percent TCAR versus 3.8 percent CEA).
        </p>
        <p class="headingAnchor" id="H3106214657">
         <span class="h4">
          TCAR surveillance project
         </span>
         <span class="headingEndMark">
          —
         </span>
         The TCAR surveillance project (TSP) remains the largest source of data on the clinical outcome of TCAR. Although not all CEA and TF-CAS procedures are captured within the Vascular Quality Initiative (VQI), over 95 percent of all TCAR procedures performed in the United States are recorded in this registry [
         <a href="#rid95">
          95
         </a>
         ]. Collection of such data provides real world outcomes. In one review of 400 consecutive patients treated with carotid revascularization, clinical practice differed from those included in carotid revascularization randomized trials in terms of patient eligibility, age, comorbidities and medications [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
         Several studies have used data from the TSP to compare outcomes between the different methods of carotid revascularization.
        </p>
        <p class="headingAnchor" id="H1403485461">
         <span class="h3">
          TCAR versus CEA
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study comparing in-hospital outcomes for patients treated between January 2016 and March 2018, 1182 TCAR patients were compared with 10,797 CEA patients. TCAR patients were older, more likely symptomatic, and had more medical comorbidities (including coronary artery disease, heart failure, and lung and kidney disease). TCAR patients were more likely to undergo redo carotid intervention, given higher rates of prior ipsilateral CEA (16 versus 2 percent) [
         <a href="#rid90">
          90
         </a>
         ]. TCAR patients were more often treated with local or regional anesthesia (20 versus 7 percent). On unadjusted analysis, TCAR had a similar rate of in-hospital stroke/death (1.6 versus 1.4 percent) and stroke/death/MI (2.5 versus 1.9 percent) compared with CEA. There was no difference in the rate of stroke (1.4 versus 1.2 percent), in-hospital death (0.3 versus 0.3 percent), 30-day death (0.9 versus 0.4 percent), or MI (1.1 versus 0.6 percent). TCAR on average was 33 minutes shorter than CEA, and the patients were less likely to incur a cranial nerve injury (0.6 versus 1.8 percent). On adjusted analysis, there was no difference in terms of stroke/death, stroke/death/MI, or the individual outcomes [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective propensity-matched cohort study compared TCAR (2692 patients) with carotid endarterectomy (8886 patients) in patients with standard surgical risk [
         <a href="#rid89">
          89
         </a>
         ]. The primary composite outcome (30-day stroke, death or myocardial infarction, or stroke at one year) was similar between the groups at 3.0 and 2.6 percent, respectively. All-cause mortality was also similar (2.6 and 2.5 percent). There was a trend toward a slight increased risk of ipsilateral stroke at one year for TCAR (1.6 versus 1.1 percent; relative risk [RR] 1.49, 95% CI 1.05-2.11).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1742516038">
         <span class="h3">
          TCAR versus TF-CAS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that compared in-hospital outcomes for 638 patients undergoing TCAR from 2016 to 2017 with 10,136 patients who underwent TF-CAS between 2005 and 2017 [
         <a href="#rid93">
          93
         </a>
         ], TCAR patients were found to be significantly older, had more cardiac comorbidities, were more likely to be symptomatic, and were less likely to have recurrent stenosis. TCAR procedures were more likely to be performed under general anesthesia (79 versus 12 percent) compared with TF-CAS. TCAR was associated with overall lower rates of in-hospital transient ischemia attacks (TIA)/stroke (1.9 versus 3.3 percent) and in-hospital TIA/stroke/death (2.2 versus 3.8 percent) compared with TF-CAS. On multivariate analysis, there was a trend but no statistically significant difference in stroke or death rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a later study using data between September 2016 and April 2019, there were 5251 TCAR procedures performed by 1035 surgeons from 319 centers [
         <a href="#rid95">
          95
         </a>
         ]. Most procedures were performed by vascular surgeons (85 percent), followed by general surgeons (9 percent), neurosurgeons (2 percent), and cardiologists (1 percent). TCAR accounted for 46 percent of all carotid stenting procedures performed in 2018. There were 6640 TF-CAS patients included in the study. After propensity score matching, 3286 pairs of patients were identified. TCAR was associated with a lower risk of in-hospital stroke or death (1.6 versus 3.1 percent), stroke (1.3 versus 2.4 percent), and death (0.4 versus 1 percent). There was no statistically significant difference in the risk of perioperative MI (0.2 versus 0.3 percent). The TCAR procedure was also associated with less radiation exposure for the patient and less contrast utilized. At one year, TCAR also had a lower risk of ipsilateral stroke or death (5.1 versus 9.6 percent).
        </p>
        <p class="headingAnchor" id="H3297237406">
         <span class="h2">
          Selecting an approach
         </span>
        </p>
        <p class="headingAnchor" id="H291484586">
         <span class="h3">
          Anatomic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of patients who may be candidates for CAS includes preoperative vascular imaging to characterize the carotid lesion and assure its patency, evaluate surrounding anatomy, and identify anatomic features that may influence the approach to CAS. (See
         <a class="medical medical_review" href="/z/d/html/1118.html" rel="external">
          "Evaluation of carotid artery stenosis"
         </a>
         .)
        </p>
        <p>
         The evaluation of the carotid lesion may include duplex ultrasonography, computed tomographic (CT) angiography, or magnetic resonance imaging or catheter angiography depending on the clinical presentation (symptomatic, asymptomatic). These are typically sufficient to characterize the carotid lesion and surrounding anatomy. For TCAR, ultrasound examination of the neck also confirms adequate anatomy for arterial sheath insertion.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For TF-CAS, CT angiography identifies any significant aortoiliac occlusive disease. For patients with occlusive disease, a decision needs to be made whether transfemoral access is feasible, or whether adjunctive endovascular procedure (eg, iliac artery angioplasty/stenting) is needed to safely achieve access. For some patients, an alternative access route may need to be selected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For TCAR, CT angiography defines anatomic candidacy related to the length of common carotid artery, presence of aortic arch atheroma, vessel tortuosity, and calcium burden within the carotid lesion.
        </p>
        <p>
        </p>
        <p>
         Cross-sectional contrast-enhanced imaging from the aortic arch through to the Circle of Willis should also be performed to identify the presence of intracranial arterial disease that may affect patient outcome.
        </p>
        <p class="headingAnchor" id="H3432763025">
         <span class="h3">
          Factors favoring TF-CAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom CAS has been selected, the following factors may favor the TF-CAS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe radiation injury in the neck
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior neck ablative surgery (laryngectomy with tracheostomy or radical neck dissection)
        </p>
        <p>
        </p>
        <p>
         The degree of radiation damage to the soft tissue in a patient who has undergone prior neck irradiation should be considered when selecting an approach for CAS. The TCAR procedure may be avoided because it requires limited dissection through a neck incision. Patients with prior neck irradiation tolerate TF-CAS with relative safety [
         <a href="#rid5">
          5,97-99
         </a>
         ]. However, in many [
         <a href="#rid100">
          100-102
         </a>
         ], but not all, studies [
         <a href="#rid103">
          103,104
         </a>
         ], the rate of late carotid restenosis and occlusion following CAS was higher in patients who had radiation-induced occlusive disease compared with those who had atherosclerotic carotid disease [
         <a href="#rid101">
          101
         </a>
         ]. A systematic review identified 27 studies that included 533 patients with radiation-induced carotid stenosis who underwent CAS or CEA [
         <a href="#rid22">
          22
         </a>
         ]. Among patients who underwent TF-CAS, the pooled estimate for any cerebrovascular adverse event was 3.9 percent, which was similar to that identified for CEA. However, the rate of restenosis &gt;50 percent and/or occlusion was significantly higher in patients treated with CAS compared with CEA (22.5 versus 10.7 percent). An earlier meta-analysis that included 21 studies found similar results [
         <a href="#rid23">
          23
         </a>
         ]. However, carotid restenosis and occlusion in these reports was largely asymptomatic.
        </p>
        <p class="headingAnchor" id="H2910258424">
         <span class="h3">
          Factors favoring TCAR
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom CAS has been selected, the following factors may favor the TCAR procedure.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral arterial disease with unfavorable peripheral artery (eg iliac, femoral) access
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heavily calcified, severely ulcerated or thrombus-lined aortic arch
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Likely inability to track and deploy a distal cerebral protection device because of marked tortuosity of the proximal internal carotid artery
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variations in aortic arch anatomy, such as a type III arch or bovine anatomy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with marked truncal obesity with groin colonization with bacteria and yeast
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &gt;80
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1360315471">
         <span class="h1">
          PERIOPERATIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfemoral CAS (TF-CAS) is most commonly performed using local anesthesia with sedation and close cardiopulmonary monitoring by the anesthesia provider. It is important for the patient to be able to communicate freely during the procedure with the anesthesia provider. The patient needs to be comfortable, but not so heavily sedated that they are disinhibited or unable to follow commands. Transcarotid artery revascularization (TCAR) may be more commonly performed using general anesthesia. In a study looking at 2609 patients undergoing TCAR, 82.3 percent were performed with general anesthesia and 17.7 percent under local anesthesia with no differences in clinical outcomes (eg, mortality, myocardial infarction [MI], neurologic events) [
         <a href="#rid105">
          105
         </a>
         ]. General anesthesia is generally recommended for TCAR proceduralists early during their experience; however, when procedural familiarity is obtained, TCAR is well suited for use of local anesthesia as with TF-CAS. (See
         <a class="medical medical_review" href="/z/d/html/90608.html" rel="external">
          "Anesthesia for carotid endarterectomy and carotid stenting"
         </a>
         .)
        </p>
        <p>
         Some degree of periprocedural bradycardia or hypotension occurs in up to 68 percent of patients who undergo CAS [
         <a href="#rid106">
          106-113
         </a>
         ]. Given that bradycardia or even cardiac arrest can develop during ballooning of the stent, both
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         and
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         should be available for immediate infusion. Bradycardia is due to carotid baroreceptor stimulation during inflation of the post-stent angioplasty balloon.
        </p>
        <p>
         Following CAS, patients are typically discharged in one to two days. Outpatient CAS may become feasible, but the safety of this practice needs to be established. Reimbursement in the United States for CAS mandates an overnight hospitalization of at least one day.
        </p>
        <p class="headingAnchor" id="H99769046">
         <span class="h2">
          Medication management
         </span>
        </p>
        <p class="headingAnchor" id="H2039239599">
         <span class="h3">
          Preoperative control of blood pressure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Poorly controlled hypertension preoperatively is predictive of prolonged length of stay due to postoperative hypertension. Thus, we make an effort to have hypertension under control before proceeding with CAS [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90608.html" rel="external">
          "Anesthesia for carotid endarterectomy and carotid stenting", section on 'Hemodynamic monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27376705">
         <span class="h3">
          Prophylactic antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although not routinely recommended for all percutaneous interventional procedures, antibiotic prophylaxis prior to CAS is standard practice, regardless of approach. Appropriate antibiotic choices are given in the table  (
         <a class="graphic graphic_table graphicRef63103" href="/z/d/graphic/63103.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H101619074">
         <span class="h3">
          Dual antiplatelet therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to CAS, we recommend pretreatment with dual antiplatelet therapy (DAPT) using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef131243" href="/z/d/graphic/131243.html" rel="external">
          algorithm 1
         </a>
         ); however, data are limited regarding the effectiveness of DAPT; the optimal timing, dose and duration of treatment for CAS is unknown [
         <a href="#rid115">
          115
         </a>
         ]. Our specific pretreatment and post-treatment dosing regimens for percutaneous CAS and TCAR are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Antiplatelet/statin therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Dual antiplatelet therapy and statins'
         </a>
         .)
        </p>
        <p>
         A systematic review identified only two small trials comparing single with dual antiplatelet therapy in patients undergoing CAS. In a meta-analysis of these two trials [
         <a href="#rid116">
          116-118
         </a>
         ], the risk for transient ischemic attack (TIA) was reduced for dual compared with single antiplatelet therapy (1.3 versus 14.6 percent; risk difference -0.13; 95% CI -0.22 to -0.05). However, there were no differences in stroke, major bleeding, or hematoma formation, or incidence of MI or death. In a separate meta-analysis of these same trials, the risk for restenosis was similar [
         <a href="#rid119">
          119
         </a>
         ]. In the absence of any other robust data, we initiate DAPT using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         prior to the procedure (at least 48 hours for percutaneous CAS; the TCAR trial favored 72 hours pretreatment) and continue dual antiplatelet therapy post-procedure for at least four weeks. Thereafter, aspirin should be continued indefinitely to reduce the risk for future cardiovascular events. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Antiplatelet therapy'
         </a>
         .)
        </p>
        <p>
         In an observational study from the Vascular Quality Initiative looking at 31,036 total CAS procedures (approximately 50/50 TCAR and TF-CAS), perioperative P2Y12 inhibitors (
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">
          prasugrel
         </a>
         , or
         <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">
          ticagrelor
         </a>
         taken within 36 hours of the procedure) markedly reduced the perioperative neurologic event rate [
         <a href="#rid120">
          120
         </a>
         ]. Among patients on P2Y12 inhibitors, 92.7 percent were also taking
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         . P2Y12 inhibitors were significantly more likely to be used in TCAR cases compared with TF-CAS cases (87.3 versus 76.8 percent). Of the patients on P2Y12 inhibitors, 77.3 percent were on clopidogrel. This study demonstrated there is considerable room for improving compliance with recommended perioperative DAPT.
        </p>
        <p>
         For patients with a history of neck irradiation, we suggest long-term DAPT with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         following CAS, provided the risk of bleeding remains low. While there are no studies available that have specifically evaluated such a protocol in this subset of patients, radiated patients are at high risk for recurrent carotid stenosis following CAS, as high as 30 percent in some series.
        </p>
        <p>
         In CAS trials, the following protocols were used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the CREST trial, patients were treated with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (325 mg twice daily) and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (75 mg twice daily) starting at least 48 hours before the CAS procedure [
         <a href="#rid4">
          4
         </a>
         ]. Those scheduled for CAS within 48 hours received aspirin 650 mg and clopidogrel 450 mg at least four hours before the CAS procedure. Following CAS, treatment included aspirin 325 mg once or twice daily and clopidogrel 75 mg daily (or
         <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">
          ticlopidine
         </a>
         250 mg twice daily) for at least 30 days, with a recommendation to continue aspirin indefinitely (at least one year).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a survey of participants of the Asymptomatic Carotid Surgery Trial 2 (ACST2 trial), 82 percent of sites used dual antiplatelet therapy (DAPT) preoperatively and 86 percent postoperatively with a mean postprocedural duration of three months (range 1 to 12), while 9 percent continued DAPT lifelong [
         <a href="#rid121">
          121
         </a>
         ]. For those prescribing postprocedural mono antiplatelet therapy (76 percent),
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         was more commonly prescribed than
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (59 versus 6 percent), and 11 percent did not show a preference for either aspirin or clopidogrel. Eleven centers (16 percent) tested for antiplatelet therapy resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the ROADSTER 2 study, early postoperative outcomes in the intention-to-treat population (692 patients) included stroke in 13 patients (1.9 percent), death in 3 patients (0.4 percent), and MI in 6 patients (0.9 percent) [
         <a href="#rid88">
          88
         </a>
         ]. Sixty patients had major protocol deviations, and among these, 48 patients were not on dual antiplatelet and statin therapy while undergoing carotid intervention or during the periprocedural follow-up period. Among the 60 patients with protocol violations, perioperative (30-day) stroke occurred in 9 (26 percent); death in 2 (3.3 percent); MI in none.
        </p>
        <p>
        </p>
        <p>
         Guidelines have suggested a range of periprocedural
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy ranging from 75 mg to 325 mg daily [
         <a href="#rid82">
          82,83,122,123
         </a>
         ]. Various loading doses of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         have also been used.
        </p>
        <p>
         Other doses of
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         have also been investigated. In the Clopidogrel and
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          Atorvastatin
         </a>
         Treatment During Carotid Artery Stenting (ARMYDA-9 CAROTID) trial, 156 patients were randomly assigned to receive a loading dose of clopidogrel (600 mg or 300 mg) before stenting with or without a statin reload (2 x 2 trial design) [
         <a href="#rid124">
          124
         </a>
         ]. The perioperative (30-day) incidence of TIA/stroke or new ischemic lesions on magnetic resonance imaging was lowest in the 600 mg clopidogrel plus statin reload group. By contrast, in a smaller trial, no differences were seen between groups for asymptomatic patients (n = 35) undergoing CAS assigned to 300 mg or 600 mg of clopidogrel with respect to the sum of all microembolic signals on transcranial Doppler, or platelet aggregation measurements [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">
          Cilostazol
         </a>
         is a phosphodiesterase inhibitor that is commonly used in the treatment of claudication. A systematic literature review identified seven studies evaluating outcomes using cilostazol in association with CAS [
         <a href="#rid126">
          126
         </a>
         ]. Major outcomes included in-stent restenosis within the observation period, revascularization rate, major/minor bleeding, and MI/stroke/death rate at 30 days and within the observation period. A significantly lower rate of in-stent stenosis was seen with cilostazol treatment after a mean follow-up of 20 months (odds ratio [OR] 0.158, 95% CI 0.072-0.349). No significant differences were found between the groups among five studies (649 patients) for periprocedural MI/stroke/death or in three studies (1076 patients) for MI/stroke/death for the entire follow-up period.
        </p>
        <p class="headingAnchor" id="H99770509">
         <span class="h3">
          Statin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Statin therapy is recommended for patients following TIA or ischemic stroke or in those with coronary artery disease risk equivalents. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">
          "Overview of secondary prevention of ischemic stroke", section on 'LDL-C lowering therapy'
         </a>
         .)
        </p>
        <p>
         Whether statin therapy can reduce the risk of cerebral embolization during or after CAS is debated [
         <a href="#rid124">
          124,127-132
         </a>
         ]. A small study compared debris collected from embolic protection devices in 62 patients who were or were not taking statins [
         <a href="#rid132">
          132
         </a>
         ]. Statin use (HMG-CoA-reductase inhibitor) was associated with significantly fewer embolic particles (16.4 versus 42.4 particles). Coronary artery disease, prior coronary artery bypass grafting, and hyperlipidemia were more prevalent in those receiving statins. The authors speculated that statin use stabilizes atherosclerotic plaque, resulting in a more fibrous plaque that is less vulnerable.
        </p>
        <p>
         Our specific pretreatment and post-treatment dosing regimens for percutaneous CAS and TCAR are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Antiplatelet/statin therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Dual antiplatelet therapy and statins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2289619141">
         <span class="h3">
          Patients requiring long-term anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A decision to stop versus bridge long-term oral anticoagulation (OAC) prior to carotid stenting is individualized and made together with the patient's cardiologist or medical physician [
         <a href="#rid133">
          133
         </a>
         ]. Regardless of whether OAC is continued or temporarily discontinued (with or without bridging anticoagulation), antiplatelet therapy (ie,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ) is initiated prior to the carotid procedure in the manner discussed above. (See
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants"
         </a>
         .)
        </p>
        <p>
         Following carotid stenting, if OAC was temporarily discontinued, it is resumed and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         initiated preoperatively are continued for at least four weeks, at which point aspirin is discontinued while clopidogrel is continued along with the anticoagulation. Any new ischemic or bleeding episodes (or change in bleeding risk) should lead to a re-evaluation of antithrombotic therapy. This approach is based on outcomes from coronary stenting. There are no data to suggest that a different approach is warranted when performing a carotid stent. (See
         <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">
          "Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Our approach'
         </a>
         .)
        </p>
        <p>
         Outcomes from studies of percutaneous coronary procedures with or without stenting also do not demonstrate any increase in adverse outcomes for uninterrupted compared with interrupted OAC, suggesting that continuing OACs is safe [
         <a href="#rid134">
          134,135
         </a>
         ]. In one retrospective review of patients undergoing CAS, among 502 patients, there were 20 patients who did not discontinue OACs. There were no complications in this group [
         <a href="#rid136">
          136
         </a>
         ]. In another review that included 511 CAS procedures, among 30 patients taking OACs, outcomes were similar to those not taking OACs [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H101620682">
         <span class="h2">
          Postprocedure care and duplex surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postprocedure care following CAS is similar to that following carotid endarterectomy [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8193.html" rel="external">
          "Carotid endarterectomy", section on 'Postoperative care'
         </a>
         .)
        </p>
        <p>
         Patients are transferred to a monitored setting for frequent blood pressure and neurologic assessment. CAS is associated with a slightly higher rate of postprocedural hypotension compared with CEA, likely related to the continued outward force of the implanted stent on the carotid body [
         <a href="#rid112">
          112,113
         </a>
         ]. As such, measures should be taken to closely monitor for this occurrence and aggressively treat postoperative hypotension.
        </p>
        <p>
         Repeat duplex ultrasonography should be obtained within three months following CAS to establish a new baseline for future comparison. Duplex surveillance is performed every six months for two years and then annually thereafter until stable (ie, no restenosis observed in two consecutive annual scans) [
         <a href="#rid137">
          137
         </a>
         ]. More frequent intervals may be warranted if a contralateral stenosis is being observed.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications associated with carotid revascularization can be grouped into systemic complications that, in general, are related to the revascularization (stroke), patient comorbidities (eg, myocardial infarction [MI], chronic kidney disease), related to the stent (in-stent restenosis, stent fracture), and related to the revascularization approach. Complications specific to the approach include complications related to arterial access or related to the embolic protection system. Approach-specific complications are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Complications'
         </a>
         .)
        </p>
        <p>
         In a study that evaluated the timing of complications following CAS, 53 percent of postoperative events/complications occurred within 6 hours of CAS, 5.3 percent between 6 and 12 hours, 8 percent between 12 and 24 hours, and 34.2 percent &gt;24 hours postprocedure [
         <a href="#rid108">
          108
         </a>
         ]. Late events &gt;24 hours were access site-related, and neurologic events included transient ischemia, minor stroke, and major stroke.
        </p>
        <p class="headingAnchor" id="H106668712">
         <span class="h2">
          Stroke
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most serious acute complication associated with CAS is stroke. Periprocedural stroke related to CAS may be due to several mechanisms, alone or in combination, including the following [
         <a href="#rid138">
          138
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thromboembolism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoperfusion due to bradycardia and/or baroreceptor stimulation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral hyperperfusion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracerebral hemorrhage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stent thrombosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Noncompliance with antiplatelet therapy
        </p>
        <p>
        </p>
        <p>
         Combined 30-day stroke and death rates for transfemoral CAS (TF-CAS) in randomized trials range from 6 to 9 percent for symptomatic patients and 2 to 4 percent for asymptomatic patients [
         <a href="#rid1">
          1,66,139
         </a>
         ]. Stroke rates have improved since the first introduction of CAS. The 30-day death and stroke rate was 3.6 percent in an analysis of two multicenter postmarket surveillance registries of CAS (EXACT, CAPTURE-2) that included 6320 high-risk patients [
         <a href="#rid77">
          77
         </a>
         ]. A similar rate was found in later large reviews [
         <a href="#rid10">
          10,79-81
         </a>
         ]. (See
         <a class="local">
          'Transfemoral carotid revascularization'
         </a>
         above.)
        </p>
        <p>
         Transcarotid artery revascularization (TCAR) appears to be associated with a lower risk for stroke compared with TF-CAS. In a study in which 3286 propensity matched pairs were studied, stroke rates were 1.3 and 2.4 percent in the TCAR and TF-CAS groups, respectively [
         <a href="#rid95">
          95
         </a>
         ]. The theoretical explanation for these observations is that TCAR eliminates the need to traverse the aortic arch during the intervention where there is often considerable concomitant atherosclerotic thromboembolic debris. The effectiveness of flow reversal in preventing distal embolization may also play a role. (See
         <a class="local">
          'Transcarotid revascularization'
         </a>
         above.)
        </p>
        <p>
         The main strategies used to reduce the risk of thromboembolic complications during and following CAS are appropriate patient selection, perioperative treatment with optimal medical therapy (including dual antiplatelet therapy [
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ] and statin), optimal intraoperative anticoagulation, strict postprocedural blood pressure control, and possibly choice of approach (TCAR versus TF-CAS) and choice of embolic protection. (See
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         above and
         <a class="local">
          'Transcarotid revascularization'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Embolic protection devices'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Establishing flow reversal and carotid stenting'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Hyperperfusion syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebral hyperperfusion syndrome is an uncommon sequela of CAS, and its occurrence after carotid stenting follows a similar path to that following carotid endarterectomy (CEA) [
         <a href="#rid140">
          140
         </a>
         ]. The syndrome is often heralded by headache ipsilateral to the revascularized internal carotid artery. Focal motor seizures and intracerebral hemorrhage may follow. As with CEA, hypertension is a frequent predecessor of the syndrome, underscoring the importance of adequate control of perioperative blood pressure. (See
         <a class="local">
          'Preoperative control of blood pressure'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15843.html" rel="external">
          "Complications of carotid endarterectomy", section on 'Hyperperfusion syndrome'
         </a>
         .)
        </p>
        <p>
         Scant data exist concerning the incidence of the hyperperfusion syndrome after carotid stenting. In a retrospective review of 450 patients treated with CAS, the following observations were made [
         <a href="#rid141">
          141
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperperfusion developed in five patients (1.1 percent), all of whom had correction of a severe internal carotid stenosis (mean 96 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All five patients with hyperperfusion syndrome had contralateral carotid stenosis &gt;80 percent or occlusion, and baseline hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracerebral hemorrhage developed in three of the five patients, two of whom developed significant periprocedural hypertension preceding the intracerebral hemorrhage. Two of the patients with intracerebral hemorrhage died.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Myocardial infarction
         </span>
         <span class="headingEndMark">
          —
         </span>
         In major randomized trials, the periprocedural incidence of MI with CAS has ranged from &lt;1 to 4 percent [
         <a href="#rid4">
          4,66
         </a>
         ]. In a study comparing 3286 propensity-matched pairs of patients undergoing TCAR and TF-CAS, there was no statistically significant difference in the risk of perioperative MI (0.2 versus 0.3 percent). In the author's experience, acute coronary syndromes can be precipitated by profound bradycardia and transient hypotension associated with ballooning the stent. Even with routine prophylactic strategies to avoid bradycardia, cardiac ischemia still sometimes occurs. Other risk factors for cardiac complications in noncardiac surgery and management of perioperative MI are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/69.html" rel="external">
          "Perioperative myocardial infarction or injury after noncardiac surgery"
         </a>
         .)
        </p>
        <p>
         Data from the National Inpatient Sample on 1,083,688 patients who underwent CEA or CAS found that 11,341 (approximately 1 percent) developed non-ST elevation MI (NSTEMI) during hospitalization. NSTEMI was associated with a significantly higher rate of in-hospital mortality (6.2 versus 0.4 percent), neurologic complications (6 versus 1.4 percent), and longer hospital stay (12.2 versus 2.8 days) [
         <a href="#rid142">
          142
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/43.html" rel="external">
          "Acute coronary syndrome: Terminology and classification"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Renal dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal dysfunction following CAS can be related to contrast-induced nephropathy, renal atheroemboli (during TF-CAS), or renal hypoperfusion due to hemodynamic instability. The risk of contrast nephropathy following CAS is greatest in patients with moderate-to-severe renal insufficiency and diabetes. (See
         <a class="medical medical_review" href="/z/d/html/7241.html" rel="external">
          "Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">
          "Prevention of contrast-associated acute kidney injury related to angiography"
         </a>
         .)
        </p>
        <p>
         Instrumentation of the aorta during TF-CAS can lead to atheroembolic events, which in turn can result in renal dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/7182.html" rel="external">
          "Clinical presentation, evaluation, and treatment of renal atheroemboli"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">
          "Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Carotid thrombosis and restenosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute and subacute in-stent thrombosis has been reported in 0.5 to 5 percent of patients with CAS [
         <a href="#rid143">
          143,144
         </a>
         ]. Some cases of carotid restenosis following CAS may be related to inadequate or discontinued antiplatelet therapy [
         <a href="#rid145">
          145-147
         </a>
         ]. Beyond 30 days, early restenosis after CAS is mainly due to neointimal hyperplasia, which is related to vascular injury related to the stent regardless of the technique used to place the stent (ie, TF-CAS, TCAR) [
         <a href="#rid148">
          148-150
         </a>
         ]. Neointimal hyperplasia related to CAS may be due to stent overdilation or imperfect positioning of the carotid stent in the vessel leading to ongoing vascular injury, and it may occur more often in women and in patients with poorly controlled diabetes or hyperlipidemia [
         <a href="#rid151">
          151
         </a>
         ]. Prior radiation is also a risk factor. Data regarding restenosis come primarily from trials and observational studies evaluating TF-CAS.
        </p>
        <p>
         Reported rates of early restenosis after CAS vary widely [
         <a href="#rid64">
          64,151-157
         </a>
         ]. In a systematic review that analyzed 34 carotid stenting studies involving 3814 arteries, angiographic restenosis, defined as ≥50 to 70 percent stenosis (a lower threshold), occurred in approximately 6 percent of arteries after one year [
         <a href="#rid152">
          152
         </a>
         ]. This compares favorably with reported rates of restenosis in the first 12 to 18 months after CEA, which range from 5.2 to 11.4 percent [
         <a href="#rid153">
          153-155
         </a>
         ]. In a review of 1060 patients, independent risk factors for restenosis ≥70 percent identified on logistic regression included hypertension (hazard ratio [HR] 6.2, 95% CI 1.9-19.9), impaired vasoreactivity (HR 1.7, 95% CI 1.09-2.8), and angioplasty without stent (HR 2.9, 95% CI 1.2-6.8) [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p>
         In the SAPPHIRE trial, target vessel revascularization (TVR) was performed for a stenosis of ≥50 percent with ischemic neurologic symptoms or a stenosis of ≥80 percent without neurologic symptoms [
         <a href="#rid64">
          64,158
         </a>
         ]. At one year after the procedure, the rate of TVR was significantly lower for the stenting group compared with the endarterectomy group (0.6 versus 4.3 percent) [
         <a href="#rid64">
          64
         </a>
         ]. At three years postprocedure, the rate of TVR remained lower for TF-CAS compared with endarterectomy (2.4 versus 5.4 percent), but the difference was not significant [
         <a href="#rid158">
          158
         </a>
         ]. In the Asymptomatic Carotid Trial I (ACT-1), the one-year rate of TVR was also lower for the stenting group (0.6 versus 2.6 percent) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         In a secondary analysis of the CREST trial, 2191 patients with appropriate postoperative ultrasonography were available for study (CAS 1086, CEA 1105) [
         <a href="#rid151">
          151
         </a>
         ]. The rates for restenosis at two years were similar for CAS compared with CEA. Female sex, diabetes, and dyslipidemia were independent predictors of restenosis or occlusion after the two procedures. Smoking predicted an increased rate of restenosis after CEA but not after CAS. At 10-year follow-up, there was no statistically significant difference in the development of restenosis or need for revascularization between transfemoral CAS and CEA (12.2 versus 9.7 percent) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         A single-center case series with long-term follow-up of 221 carotid stenting procedures on 193 patients showed a restenosis rate (&gt;50 percent on duplex scan) at 10 years was 6.8 percent [
         <a href="#rid159">
          159
         </a>
         ]. [
         <a href="#rid152">
          152
         </a>
         ]
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Stent fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stent fracture may be a common complication of CAS, but its clinical significance is unknown. Data regarding stent fracture come from studies evaluating TF-CAS. In a retrospective report of 48 carotid stents in 43 patients, stent fracture was detected at a mean radiologic follow-up of 18 months in 29 percent [
         <a href="#rid160">
          160
         </a>
         ]. The risk of stent fracture was associated with the presence of arterial calcification in the region of the deployed stent (odds ratio 7.7, 95% CI 1.9-32.0). Restenosis &gt;50 percent was present in 3 of the 14 fractured stents and 3 of 34 stents without fracture. In a review of the outcomes of the ACT-1 trial, in which CAS was used in 1021 standard surgical risk patients with asymptomatic carotid stenosis, stent fracture was detected in 5.4 percent of 939 patients who had at least one radiograph during follow-up [
         <a href="#rid161">
          161
         </a>
         ]. There was no association between stent fracture and the occurrence of carotid restenosis or for a primary composite endpoint of stroke, death, or MI.
        </p>
        <p class="headingAnchor" id="H1016119220">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117201.html" rel="external">
          "Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24094361">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15819.html" rel="external">
          "Patient education: Carotid artery disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carotid artery stenting
         </strong>
         – Carotid artery stenting (CAS) can be performed percutaneously (eg, transfemoral CAS [TF-CAS]) or through a small incision in the neck (ie, transcarotid artery revascularization [TCAR]). A technical comparison of these methods is provided above. During CAS, several methods of embolic protection are used and are intended to prevent stroke; however, the superiority of one method over another, and furthermore, an overall benefit has not been definitively established. (See
         <a class="local">
          'Approach to carotid artery stenting'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilateral carotid stenosis
         </strong>
         – For patients with severe bilateral carotid stenosis, we prefer a staged approach rather than simultaneous CAS. Simultaneous CAS theoretically increases the risk for cerebral hyperperfusion syndrome, as well as severe bradycardia or hypotension related to bilateral baroreceptor irritation. (See
         <a class="local">
          'Timing and other considerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiplatelet therapy
         </strong>
         – For patients in whom CAS is scheduled or anticipated, we recommend pretreatment with dual antiplatelet therapy (DAPT) using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , rather than monotherapy or no antiplatelet therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration of therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         DAPT is continued for at least four weeks after the procedure.
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         alone is subsequently continued indefinitely to reduce the risk of future cardiovascular events. (See
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with a history of neck irradiation, we suggested continuing DAPT using
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         indefinitely (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Radiated patients are at high risk for recurrent carotid stenosis following CAS (See
         <a class="local">
          'Dual antiplatelet therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing regimens
         </strong>
         – Specific pre- and post-treatment DAPT dosing regimens for TF-CAS and TCAR are provided separately. Statin therapy is also recommended. (See
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Antiplatelet/statin therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Dual antiplatelet therapy and statins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stroke
         </strong>
         – The most serious acute complication associated with carotid artery stenting (CAS) is stroke, which can occur due to thromboembolism, hypoperfusion, hyperperfusion syndrome, or hemorrhage. Potential factors that have an impact on the risk of stroke with CAS include older age, carotid plaque morphology, prior neck irradiation, and contralateral carotid occlusive disease. The main strategies used to reduce the risk of thromboembolic complications during and following CAS are appropriate patient selection, perioperative treatment with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (dual antiplatelet therapy), and optimal intraoperative anticoagulation. (See
         <a class="local">
          'Complications'
         </a>
         above and
         <a class="local">
          'Risk assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other complications
         </strong>
         – Other complications associated with CAS include access-related issues (eg, hematoma, bleeding, pseudoaneurysm formation, and distal atheroembolization), myocardial infarction, contrast-related renal failure, restenosis of the target lesion, and carotid stent fracture. (See
         <a class="local">
          'Complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/127412.html" rel="external">
          "Percutaneous carotid artery stenting", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/127009.html" rel="external">
          "Transcarotid artery revascularization", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H297043205">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.
        </p>
        <p>
         The editorial staff at UpToDate also acknowledges Ronald M Fairman, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           SPACE Collaborative Group, Ringleb PA, Allenberg J, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voeks JH, Howard G, Roubin GS, et al. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke 2011; 42:3484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hobson RW 2nd, Howard VJ, Roubin GS, et al. Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg 2004; 40:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roubin GS, New G, Iyer SS, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. Circulation 2001; 103:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann R, Niessner A, Kypta A, et al. Risk score for peri-interventional complications of carotid artery stenting. Stroke 2006; 37:2557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaturvedi S, Matsumura JS, Gray W, et al. Carotid artery stenting in octogenarians: periprocedural stroke risk predictor analysis from the multicenter Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events (CAPTURE 2) clinical trial. Stroke 2010; 41:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathur A, Roubin GS, Iyer SS, et al. Predictors of stroke complicating carotid artery stenting. Circulation 1998; 97:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoniou GA, Georgiadis GS, Georgakarakos EI, et al. Meta-analysis and meta-regression analysis of outcomes of carotid endarterectomy and stenting in the elderly. JAMA Surg 2013; 148:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jalbert JJ, Nguyen LL, Gerhard-Herman MD, et al. Outcomes after carotid artery stenting in Medicare beneficiaries, 2005 to 2009. JAMA Neurol 2015; 72:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam RC, Lin SC, DeRubertis B, et al. The impact of increasing age on anatomic factors affecting carotid angioplasty and stenting. J Vasc Surg 2007; 45:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaer RA, Shen J, Rao A, et al. Cerebral reserve is decreased in elderly patients with carotid stenosis. J Vasc Surg 2010; 52:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dakour-Aridi H, Kashyap VS, Wang GJ, et al. The impact of age on in-hospital outcomes after transcarotid artery revascularization, transfemoral carotid artery stenting, and carotid endarterectomy. J Vasc Surg 2020; 72:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rockman CB, Garg K, Jacobowitz GR, et al. Outcome of carotid artery interventions among female patients, 2004 to 2005. J Vasc Surg 2011; 53:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard VJ, Lutsep HL, Mackey A, et al. Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Lancet Neurol 2011; 10:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vouyouka AG, Egorova NN, Sosunov EA, et al. Analysis of Florida and New York state hospital discharges suggests that carotid stenting in symptomatic women is associated with significant increase in mortality and perioperative morbidity compared with carotid endarterectomy. J Vasc Surg 2012; 56:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisdas T, Egorova N, Moskowitz AJ, et al. The impact of gender on in-hospital outcomes after carotid endarterectomy or stenting. Eur J Vasc Endovasc Surg 2012; 44:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett KM, Scarborough JE. Carotid artery stenting is associated with a higher incidence of major adverse clinical events than carotid endarterectomy in female patients. J Vasc Surg 2017; 66:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AbuRahma AF, DerDerian T, Hariri N, et al. Anatomical and technical predictors of perioperative clinical outcomes after carotid artery stenting. J Vasc Surg 2017; 66:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi AI, Luft AR, Janardhan V, et al. Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting. Stroke 2000; 31:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voeks JH, Howard G, Roubin G, et al. Mediators of the Age Effect in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke 2015; 46:2868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fokkema M, den Hartog AG, Bots ML, et al. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke 2012; 43:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasivisvanathan V, Thapar A, Davies KJ, et al. Periprocedural outcomes after surgical revascularization and stenting for postradiotherapy carotid stenosis. J Vasc Surg 2012; 56:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ederle J, Davagnanam I, van der Worp HB, et al. Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial. Lancet Neurol 2013; 12:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrup A, Gröschel K, Schulz JB, et al. Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. Stroke 2005; 36:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson BM, English SJ, Fairman RM, et al. Carotid artery stenting: identification of risk factors for poor outcomes. J Vasc Surg 2008; 48:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reimers B, Schlüter M, Castriota F, et al. Routine use of cerebral protection during carotid artery stenting: results of a multicenter registry of 753 patients. Am J Med 2004; 116:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard VJ, Voeks JH, Lutsep HL, et al. Does sex matter? Thirty-day stroke and death rates after carotid artery stenting in women versus men: results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) lead-in phase. Stroke 2009; 40:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donahue M, Visconti G, Focaccio A, et al. Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Internal Carotid Artery Stent Implantation. JACC Cardiovasc Interv 2015; 8:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faggioli G, Pini R, Rapezzi C, et al. Carotid revascularization in patients with ongoing oral anticoagulant therapy: the advantages of stent placement. J Vasc Interv Radiol 2013; 24:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White CJ, Ramee SR, Collins TJ, et al. Carotid stents to prevent stroke: a nonsurgical option. Ochsner J 2003; 5:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson E, Fox AJ. Carotid Near-Occlusion: A Comprehensive Review, Part 1--Definition, Terminology, and Diagnosis. AJNR Am J Neuroradiol 2016; 37:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson E, Fox AJ. Carotid Near-Occlusion: A Comprehensive Review, Part 2--Prognosis and Treatment, Pathophysiology, Confusions, and Areas for Improvement. AJNR Am J Neuroradiol 2016; 37:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meschia JF, Hopkins LN, Altafullah I, et al. Time From Symptoms to Carotid Endarterectomy or Stenting and Perioperative Risk. Stroke 2015; 46:3540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Rango P, Brown MM, Chaturvedi S, et al. Summary of Evidence on Early Carotid Intervention for Recently Symptomatic Stenosis Based on Meta-Analysis of Current Risks. Stroke 2015; 46:3423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry M, Gopalakrishnan L, Rajagopal S, et al. Bilateral carotid angioplasty and stenting. Catheter Cardiovasc Interv 2005; 64:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehm N, Katzen BT, Iyer SS, et al. Staged bilateral carotid stenting, an effective strategy in high-risk patients - insights from a prospective multicenter trial. J Vasc Surg 2008; 47:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, Jung JH, Kim SM, et al. Simultaneous bilateral carotid stenting in high-risk patients. AJNR Am J Neuroradiol 2010; 31:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kedev S, Petkoska D, Zafirovska B, et al. Safety of Slender 5Fr Transradial Approach for Carotid Artery Stenting With a Novel Nitinol Double-Layer Micromesh Stent. Am J Cardiol 2015; 116:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzoni R, Roffi M. Transradial access for peripheral and cerebrovascular interventions. J Invasive Cardiol 2013; 25:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etxegoien N, Rhyne D, Kedev S, et al. The transradial approach for carotid artery stenting. Catheter Cardiovasc Interv 2012; 80:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruzsa Z, Nemes B, Pintér L, et al. A randomised comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR (RADial access for CARotid artery stenting) study. EuroIntervention 2014; 10:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinter L, Ribo M, Loh C, et al. Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study. J Vasc Surg 2011; 54:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez B, Matas M, Ribo M, et al. Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years. J Vasc Surg 2012; 55:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leal I, Orgaz A, Flores Á, et al. A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection. J Vasc Surg 2012; 56:1585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sfyroeras GS, Moulakakis KG, Markatis F, et al. Results of carotid artery stenting with transcervical access. J Vasc Surg 2013; 58:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda Y, Terada T, Masuo O, et al. The clinical results of transcervical carotid artery stenting and frequency chosen as the approach route of carotid artery stenting in 1,067 consecutive cases. Acta Neurochir (Wien) 2013; 155:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortega G, Álvarez B, Quintana M, et al. Cognitive improvement in patients with severe carotid artery stenosis after transcervical stenting with protective flow reversal. Cerebrovasc Dis 2013; 35:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopoulos D, Philippov E. The results of a simplified technique for safe carotid stenting in the elderly. J Vasc Surg 2011; 54:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palombo G, Stella N, Faraglia V, et al. Cervical access for filter-protected carotid artery stenting: a useful tool to reduce cerebral embolisation. Eur J Vasc Endovasc Surg 2010; 39:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopoulos D, Philippov E, Kallintzi M. Safe carotid artery angioplasty and stenting in patients unsuitable for transfemoral approach. Int Angiol 2010; 29:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flores A, Doblas M, Criado E. Transcervical carotid artery stenting with flow reversal eliminates emboli during stenting: why does it work and what are the advantages with this approach. J Cardiovasc Surg (Torino) 2009; 50:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faraglia V, Palombo G, Stella N, et al. Cerebral embolization during transcervical carotid stenting with flow reversal: a diffusion-weighted magnetic resonance study. Ann Vasc Surg 2009; 23:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criado E, Fontcuberta J, Orgaz A, et al. Transcervical carotid stenting with carotid artery flow reversal: 3-year follow-up of 103 stents. J Vasc Surg 2007; 46:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matas M, Alvarez B, Ribo M, et al. Transcervical carotid stenting with flow reversal protection: experience in high-risk patients. J Vasc Surg 2007; 46:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandrescu V, Ngongang C, Proumen J, et al. Filter-protected carotid stenting via a minimal cervical access with transitory aspirated reversed flow during initial passage of the target lesion. J Endovasc Ther 2006; 13:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JC, Kolvenbach RR, Pinter L. Protected carotid artery stenting and angioplasty via transfemoral versus transcervical approaches. Vasc Endovascular Surg 2005; 39:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pipinos II, Johanning JM, Pham CN, et al. Transcervical approach with protective flow reversal for carotid angioplasty and stenting. J Endovasc Ther 2005; 12:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo CH, Doblas M, Criado E. Advantages and indications of transcervical carotid artery stenting with carotid flow reversal. J Cardiovasc Surg (Torino) 2005; 46:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criado E, Doblas M, Fontcuberta J, et al. Transcervical carotid stenting with internal carotid artery flow reversal: feasibility and preliminary results. J Vasc Surg 2004; 40:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang DW, Schubart PJ, Veith FJ, Zarins CK. A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention. J Vasc Surg 2004; 39:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield K, Matsumura JS, Chaturvedi S, et al. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. N Engl J Med 2016; 374:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mas JL, Trinquart L, Leys D, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008; 7:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadav JS. Carotid stenting in high-risk patients: design and rationale of the SAPPHIRE trial. Cleve Clin J Med 2004; 71 Suppl 1:S45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           International Carotid Stenting Study investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010; 375:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonati LH, Dobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 2015; 385:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen DJ, Stolker JM, Wang K, et al. Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). J Am Coll Cardiol 2011; 58:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brott TG, Howard G, Roubin GS, et al. Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. N Engl J Med 2016; 374:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincent S, Eberg M, Eisenberg MJ, Filion KB. Meta-Analysis of Randomized Controlled Trials Comparing the Long-Term Outcomes of Carotid Artery Stenting Versus Endarterectomy. Circ Cardiovasc Qual Outcomes 2015; 8:S99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Economopoulos KP, Sergentanis TN, Tsivgoulis G, et al. Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes. Stroke 2011; 42:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim LK, Yang DC, Swaminathan RV, et al. Comparison of trends and outcomes of carotid artery stenting and endarterectomy in the United States, 2001 to 2010. Circ Cardiovasc Interv 2014; 7:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brott TG, Calvet D, Howard G, et al. Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data. Lancet Neurol 2019; 18:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonati LH, Lyrer P, Ederle J, et al. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012; :CD000515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sardar P, Chatterjee S, Aronow HD, et al. Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention: A Meta-Analysis of Clinical Trials. J Am Coll Cardiol 2017; 69:2266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moresoli P, Habib B, Reynier P, et al. Carotid Stenting Versus Endarterectomy for Asymptomatic Carotid Artery Stenosis: A Systematic Review and Meta-Analysis. Stroke 2017; 48:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray WA, Chaturvedi S, Verta P, Investigators and the Executive Committees. Thirty-day outcomes for carotid artery stenting in 6320 patients from 2 prospective, multicenter, high-surgical-risk registries. Circ Cardiovasc Interv 2009; 2:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massop D, Dave R, Metzger C, et al. Stenting and angioplasty with protection in patients at high-risk for endarterectomy: SAPPHIRE Worldwide Registry first 2,001 patients. Catheter Cardiovasc Interv 2009; 73:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi JC, Johnston SC, Kim AS. Early outcomes after carotid artery stenting compared with endarterectomy for asymptomatic carotid stenosis. Stroke 2015; 46:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan BW, De Martino RR, Goodney PP, et al. Comparison of carotid endarterectomy and stenting in real world practice using a regional quality improvement registry. J Vasc Surg 2012; 56:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mudra H, Staubach S, Hein-Rothweiler R, et al. Long-Term Outcomes of Carotid Artery Stenting in Clinical Practice. Circ Cardiovasc Interv 2016; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AbuRahma AF, Avgerinos ED, Chang RW, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg 2022; 75:4S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AbuRahma AF, Avgerinos ED, Chang RW, et al. The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease. J Vasc Surg 2022; 75:26S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alpaslan A, Wintermark M, Pintér L, et al. Transcarotid Artery Revascularization With Flow Reversal. J Endovasc Ther 2017; 24:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwolek CJ, Jaff MR, Leal JI, et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg 2015; 62:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malas MB, Leal Lorenzo JI, Nejim B, et al. Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal. J Vasc Surg 2019; 69:1786.
          </a>
         </li>
         <li class="breakAll">
          Kashyap V. Analysis of the early outcomes in the ROADSTER 2 clinical trial of transcarotid artery revascularization in patients with significant carotid artery disease. Abstract and oral presentation, Society for Vascular Surgery Vascular Annual Meeting 2019, National Harbor, MD, June 2019.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashyap VS, Schneider PA, Foteh M, et al. Early Outcomes in the ROADSTER 2 Study of Transcarotid Artery Revascularization in Patients With Significant Carotid Artery Disease. Stroke 2020; 51:2620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang P, Cronenwett JL, Secemsky EA, et al. Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk. JAMA Neurol 2023; 80:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schermerhorn ML, Liang P, Dakour-Aridi H, et al. In-hospital outcomes of transcarotid artery revascularization and carotid endarterectomy in the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg 2020; 71:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Columbo JA, Martinez-Camblor P, O'Malley AJ, et al. Association of Adoption of Transcarotid Artery Revascularization With Center-Level Perioperative Outcomes. JAMA Netw Open 2021; 4:e2037885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AbuRahma AF, Santini A, AbuRahma ZT, et al. Thirty-Day Perioperative Clinical Outcomes of Transcarotid Artery Revascularization vs Carotid Endarterectomy in a Single-Center Experience. J Am Coll Surg 2023; 236:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malas MB, Dakour-Aridi H, Wang GJ, et al. Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg 2019; 69:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashyap VS, King AH, Foteh MI, et al. A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy. J Vasc Surg 2019; 70:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schermerhorn ML, Liang P, Eldrup-Jorgensen J, et al. Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis. JAMA 2019; 322:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallmayer MA, Knappich C, Karlas A, et al. External Validity of Randomised Controlled Trials on Carotid Revascularisation: Trial Populations May Not Always Reflect Patients in Clinical Practice. Eur J Vasc Endovasc Surg 2022; 64:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorresteijn LD, Vogels OJ, de Leeuw FE, et al. Outcome of carotid artery stenting for radiation-induced stenosis. Int J Radiat Oncol Biol Phys 2010; 77:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shawl FA. Carotid artery stenting: acute and long-term results. Curr Opin Cardiol 2002; 17:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Mubarak N, Roubin GS, Iyer SS, et al. Carotid stenting for severe radiation-induced extracranial carotid artery occlusive disease. J Endovasc Ther 2000; 7:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin SH, Stout CL, Richardson AI, et al. Carotid angioplasty and stenting in anatomically high-risk patients: Safe and durable except for radiation-induced stenosis. J Vasc Surg 2009; 50:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Protack CD, Bakken AM, Saad WE, et al. Radiation arteritis: a contraindication to carotid stenting? J Vasc Surg 2007; 45:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skelly CL, Gallagher K, Fairman RM, et al. Risk factors for restenosis after carotid artery angioplasty and stenting. J Vasc Surg 2006; 44:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallarita T, Oderich GS, Lanzino G, et al. Outcomes of carotid artery stenting versus historical surgical controls for radiation-induced carotid stenosis. J Vasc Surg 2011; 53:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskandari MK, Brown KE, Kibbe MR, et al. Restenosis after carotid stent placement in patients with previous neck irradiation or endarterectomy. J Vasc Interv Radiol 2007; 18:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukherjee D, Collins DT, Liu C, et al. The study of transcarotid artery revascularization under local versus general anesthesia with results from the Society for Vascular Surgery Vascular Quality Initiative. Vascular 2020; 28:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mylonas SN, Moulakakis KG, Antonopoulos CN, et al. Carotid artery stenting-induced hemodynamic instability. J Endovasc Ther 2013; 20:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi AI, Luft AR, Sharma M, et al. Frequency and determinants of postprocedural hemodynamic instability after carotid angioplasty and stenting. Stroke 1999; 30:2086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan KT, Cleveland TJ, Berczi V, et al. Timing and frequency of complications after carotid artery stenting: what is the optimal period of observation? J Vasc Surg 2003; 38:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ullery BW, Nathan DP, Shang EK, et al. Incidence, predictors, and outcomes of hemodynamic instability following carotid angioplasty and stenting. J Vasc Surg 2013; 58:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelsohn FO, Weissman NJ, Lederman RJ, et al. Acute hemodynamic changes during carotid artery stenting. Am J Cardiol 1998; 82:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Abou-Chebl A, Bajzer CT, et al. Rate, predictors, and consequences of hemodynamic depression after carotid artery stenting. J Am Coll Cardiol 2006; 47:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin PH, Zhou W, Kougias P, et al. Factors associated with hypotension and bradycardia after carotid angioplasty and stenting. J Vasc Surg 2007; 46:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park BD, Divinagracia T, Madej O, et al. Predictors of clinically significant postprocedural hypotension after carotid endarterectomy and carotid angioplasty with stenting. J Vasc Surg 2009; 50:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoneham MD, Thompson JP. Arterial pressure management and carotid endarterectomy. Br J Anaesth 2009; 102:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matas M, Domínguez González JM, Montull E. Antiplatelet therapy in endovascular surgery: the RENDOVASC study. Ann Vasc Surg 2013; 27:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barkat M, Hajibandeh S, Hajibandeh S, et al. Systematic Review and Meta-analysis of Dual Versus Single Antiplatelet Therapy in Carotid Interventions. Eur J Vasc Endovasc Surg 2017; 53:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalainas I, Nano G, Bianchi P, et al. Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol 2006; 29:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKevitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 2005; 29:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peeters Weem SM, van Haelst ST, den Ruijter HM, et al. Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. Eur J Vasc Endovasc Surg 2016; 52:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heib A, Chang H, Rockman C, et al. Periprocedural P2Y12 inhibitors improve perioperative outcomes after carotid stenting by primarily decreasing strokes. J Vasc Surg 2023; 77:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huibers A, Halliday A, Bulbulia R, et al. Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2. Eur J Vasc Endovasc Surg 2016; 51:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naylor R, Rantner B, Ancetti S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg 2023; 65:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. Stroke 2011; 42:e420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patti G, Tomai F, Melfi R, et al. Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. J Am Coll Cardiol 2013; 61:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Der Heyden J, Van Werkum J, Hackeng CM, et al. High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial. J Cardiovasc Surg (Torino) 2013; 54:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galyfos G, Geropapas G, Sigala F, et al. Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting. J Endovasc Ther 2016; 23:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiff T, Amiri H, Rohde S, et al. Statins reduce peri-procedural complications in carotid stenting. Eur J Vasc Endovasc Surg 2014; 48:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizwan M, Faateh M, Dakour-Aridi H, et al. Statins reduce mortality and failure to rescue after carotid artery stenting. J Vasc Surg 2019; 69:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krafcik BM, Farber A, Eberhardt RT, et al. Preoperative Antiplatelet and Statin Use Does Not Affect Outcomes after Carotid Endarterectomy. Ann Vasc Surg 2018; 46:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Texakalidis P, Giannopoulos S, Jonnalagadda AK, et al. Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. J Endovasc Ther 2018; 25:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong JH, Sohn SI, Kwak J, et al. Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke 2017; 48:1890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tadros RO, Vouyouka AG, Chung C, et al. The effect of statin use on embolic potential during carotid angioplasty and stenting. Ann Vasc Surg 2013; 27:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brand AR, de Borst GJ. Evidence for periprocedural antiplatelet therapy, heparinization and bridging of coumarin therapy in carotid revascularization. J Cardiovasc Surg (Torino) 2017; 58:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowalewski M, Suwalski P, Raffa GM, et al. Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. Int J Cardiol 2016; 223:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahi V, Brinjikji W, Murad MH, et al. Safety of Uninterrupted Warfarin Therapy in Patients Undergoing Cardiovascular Endovascular Procedures: A Systematic Review and Meta-Analysis. Radiology 2016; 278:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pini R, Faggioli G, Mauro R, et al. Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of perioperative bridging heparin therapy. Thromb Res 2012; 130:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. J Vasc Surg 2018; 68:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulakakis KG, Mylonas SN, Lazaris A, et al. Acute Carotid Stent Thrombosis: A Comprehensive Review. Vasc Endovascular Surg 2016; 50:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timaran CH, Veith FJ, Rosero EB, et al. Intracranial hemorrhage after carotid endarterectomy and carotid stenting in the United States in 2005. J Vasc Surg 2009; 49:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abou-Chebl A, Yadav JS, Reginelli JP, et al. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting: risk factors, prevention, and treatment. J Am Coll Cardiol 2004; 43:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan A, Adil MM, Qureshi AI. Non-ST-elevation myocardial infarction in patients undergoing carotid endarterectomy or carotid artery stent placement. Stroke 2014; 45:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roubin GS, Yadav S, Iyer SS, Vitek J. Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke. Am J Cardiol 1996; 78:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg 1996; 3:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong FC, Cloft HJ, Joseph GJ, et al. Abciximab rescue in acute carotid stent thrombosis. AJNR Am J Neuroradiol 2000; 21:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaturvedi S, Sohrab S, Tselis A. Carotid stent thrombosis: report of 2 fatal cases. Stroke 2001; 32:2700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhk JH, Wellmer A, Knauth M. Late in-stent thrombosis following carotid angioplasty and stenting. Neurology 2006; 66:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonati LH, Gregson J, Dobson J, et al. Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. Lancet Neurol 2018; 17:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lattimer CR, Burnand KG. Recurrent carotid stenosis after carotid endarterectomy. Br J Surg 1997; 84:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willfort-Ehringer A, Ahmadi R, Gschwandtner ME, et al. Healing of carotid stents: a prospective duplex ultrasound study. J Endovasc Ther 2003; 10:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lal BK, Beach KW, Roubin GS, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol 2012; 11:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gröschel K, Riecker A, Schulz JB, et al. Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke 2005; 36:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frericks H, Kievit J, van Baalen JM, van Bockel JH. Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature. Stroke 1998; 29:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore WS, Kempczinski RF, Nelson JJ, Toole JF. Recurrent carotid stenosis : results of the asymptomatic carotid atherosclerosis study. Stroke 1998; 29:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCabe DJ, Pereira AC, Clifton A, et al. Restenosis after carotid angioplasty, stenting, or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS). Stroke 2005; 36:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorigo W, Pulli R, Fargion A, et al. Comparison of open and endovascular treatments of post-carotid endarterectomy restenosis. Eur J Vasc Endovasc Surg 2013; 45:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapata-Arriaza E, Moniche F, González A, et al. Predictors of Restenosis Following Carotid Angioplasty and Stenting. Stroke 2016; 47:2144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 2008; 358:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeron P, Roux M, Khanoyan P, et al. Long-term results of carotid stenting are competitive with surgery. J Vasc Surg 2005; 41:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling AJ, Mwipatayi P, Gandhi T, Sieunarine K. Stenting for carotid artery stenosis: fractures, proposed etiology and the need for surveillance. J Vasc Surg 2008; 47:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg I, Beckman JA, Matsumura JS, et al. Carotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease). Circulation 2018; 137:49.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1104 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17027729" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21980205" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15622363" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20505173" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Stenting versus endarterectomy for treatment of carotid-artery stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157718" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16990579" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk score for peri-interventional complications of carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20185789" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Carotid artery stenting in octogenarians: periprocedural stroke risk predictor analysis from the multicenter Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events (CAPTURE 2) clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9570193" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Predictors of stroke complicating carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24154858" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Meta-analysis and meta-regression analysis of outcomes of carotid endarterectomy and stenting in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25580726" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Outcomes after carotid artery stenting in Medicare beneficiaries, 2005 to 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17466784" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The impact of increasing age on anatomic factors affecting carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20620003" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cerebral reserve is decreased in elderly patients with carotid stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32035784" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The impact of age on in-hospital outcomes after transcarotid artery revascularization, transfemoral carotid artery stenting, and carotid endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514770" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Outcome of carotid artery interventions among female patients, 2004 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21550314" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22583852" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Analysis of Florida and New York state hospital discharges suggests that carotid stenting in symptomatic women is associated with significant increase in mortality and perioperative morbidity compared with carotid endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22819738" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The impact of gender on in-hospital outcomes after carotid endarterectomy or stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28502547" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Carotid artery stenting is associated with a higher incidence of major adverse clinical events than carotid endarterectomy in female patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28559171" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Anatomical and technical predictors of perioperative clinical outcomes after carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10657409" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Identification of patients at risk for periprocedural neurological deficits associated with carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26351359" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Mediators of the Age Effect in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22207504" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22819749" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Periprocedural outcomes after surgical revascularization and stenting for postradiotherapy carotid stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23849948" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705938" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18502085" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Carotid artery stenting: identification of risk factors for poor outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14969648" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Routine use of cerebral protection during carotid artery stenting: results of a multicenter registry of 753 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19211486" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Does sex matter? Thirty-day stroke and death rates after carotid artery stenting in women versus men: results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) lead-in phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26298226" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Internal Carotid Artery Stent Implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433413" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Carotid revascularization in patients with ongoing oral anticoagulant therapy: the advantages of stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22493566" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Carotid stents to prevent stroke: a nonsurgical option.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26316571" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Carotid Near-Occlusion: A Comprehensive Review, Part 1--Definition, Terminology, and Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26338908" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Carotid Near-Occlusion: A Comprehensive Review, Part 2--Prognosis and Treatment, Pathophysiology, Confusions, and Areas for Improvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26493675" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Time From Symptoms to Carotid Endarterectomy or Stenting and Perioperative Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26470773" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Summary of Evidence on Early Carotid Intervention for Recently Symptomatic Stenosis Based on Meta-Analysis of Current Risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15736256" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bilateral carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440179" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Staged bilateral carotid stenting, an effective strategy in high-risk patients - insights from a prospective multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20053810" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Simultaneous bilateral carotid stenting in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26189035" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Safety of Slender 5Fr Transradial Approach for Carotid Artery Stenting With a Novel Nitinol Double-Layer Micromesh Stent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24088428" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Transradial access for peripheral and cerebrovascular interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22639455" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The transradial approach for carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25042266" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A randomised comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR (RADial access for CARotid artery stenting) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21658889" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22322116" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Transcervical carotid stenting with flow reversal is a safe technique for high-risk patients older than 70 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22960021" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A diffusion-weighted magnetic resonance imaging-based study of transcervical carotid stenting with flow reversal versus transfemoral filter protection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24074938" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Results of carotid artery stenting with transcervical access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23653167" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The clinical results of transcervical carotid artery stenting and frequency chosen as the approach route of carotid artery stenting in 1,067 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23406878" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cognitive improvement in patients with severe carotid artery stenosis after transcervical stenting with protective flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890307" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The results of a simplified technique for safe carotid stenting in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19945315" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cervical access for filter-protected carotid artery stenting: a useful tool to reduce cerebral embolisation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20224530" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Safe carotid artery angioplasty and stenting in patients unsuitable for transfemoral approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935605" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Transcervical carotid artery stenting with flow reversal eliminates emboli during stenting: why does it work and what are the advantages with this approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19041221" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cerebral embolization during transcervical carotid stenting with flow reversal: a diffusion-weighted magnetic resonance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980271" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Transcervical carotid stenting with carotid artery flow reversal: 3-year follow-up of 103 stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606121" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Transcervical carotid stenting with flow reversal protection: experience in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16643074" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Filter-protected carotid stenting via a minimal cervical access with transitory aspirated reversed flow during initial passage of the target lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16382271" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Protected carotid artery stenting and angioplasty via transfemoral versus transcervical approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048376" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Transcervical approach with protective flow reversal for carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15956920" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Advantages and indications of transcervical carotid artery stenting with carotid flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337876" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Transcervical carotid stenting with internal carotid artery flow reversal: feasibility and preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15111851" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26886419" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18774745" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15470212" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Protected carotid-artery stenting versus endarterectomy in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14964484" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Carotid stenting in high-risk patients: design and rationale of the SAPPHIRE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189239" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25453443" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21958882" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26890472" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26515216" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Meta-Analysis of Randomized Controlled Trials Comparing the Long-Term Outcomes of Carotid Artery Stenting Versus Endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233476" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25116802" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Comparison of trends and outcomes of carotid artery stenting and endarterectomy in the United States, 2001 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30738706" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972047" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28473130" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention: A Meta-Analysis of Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28679848" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Carotid Stenting Versus Endarterectomy for Asymptomatic Carotid Artery Stenosis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031712" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Thirty-day outcomes for carotid artery stenting in 6320 patients from 2 prospective, multicenter, high-surgical-risk registries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18924164" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Stenting and angioplasty with protection in patients at high-risk for endarterectomy: SAPPHIRE Worldwide Registry first 2,001 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25424479" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Early outcomes after carotid artery stenting compared with endarterectomy for asymptomatic carotid stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22579135" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Comparison of carotid endarterectomy and stenting in real world practice using a regional quality improvement registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27582114" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Long-Term Outcomes of Carotid Artery Stenting in Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34153348" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34153349" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28335706" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Transcarotid Artery Revascularization With Flow Reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26506270" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30611582" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30611582" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32811386" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Early Outcomes in the ROADSTER 2 Study of Transcarotid Artery Revascularization in Patients With Significant Carotid Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36939697" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31227410" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : In-hospital outcomes of transcarotid artery revascularization and carotid endarterectomy in the Society for Vascular Surgery Vascular Quality Initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33616666" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Association of Adoption of Transcarotid Artery Revascularization With Center-Level Perioperative Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36728406" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Thirty-Day Perioperative Clinical Outcomes of Transcarotid Artery Revascularization vs Carotid Endarterectomy in a Single-Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29941316" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30622007" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31846015" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Association of Transcarotid Artery Revascularization vs Transfemoral Carotid Artery Stenting With Stroke or Death Among Patients With Carotid Artery Stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35987505" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : External Validity of Randomised Controlled Trials on Carotid Revascularisation: Trial Populations May Not Always Reflect Patients in Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20116932" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Outcome of carotid artery stenting for radiation-induced stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12466711" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Carotid artery stenting: acute and long-term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10772747" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Carotid stenting for severe radiation-induced extracranial carotid artery occlusive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786237" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Carotid angioplasty and stenting in anatomically high-risk patients: Safe and durable except for radiation-induced stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17210394" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Radiation arteritis: a contraindication to carotid stenting?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17098535" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Risk factors for restenosis after carotid artery angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21216558" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Outcomes of carotid artery stenting versus historical surgical controls for radiation-induced carotid stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18003986" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Restenosis after carotid stent placement in patients with previous neck irradiation or endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32408855" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The study of transcarotid artery revascularization under local versus general anesthesia with results from the Society for Vascular Surgery Vascular Quality Initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23391083" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Carotid artery stenting-induced hemodynamic instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10512911" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Frequency and determinants of postprocedural hemodynamic instability after carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891103" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Timing and frequency of complications after carotid artery stenting: what is the optimal period of observation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23669182" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Incidence, predictors, and outcomes of hemodynamic instability following carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9817485" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Acute hemodynamic changes during carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16630988" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Rate, predictors, and consequences of hemodynamic depression after carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17980268" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Factors associated with hypotension and bradycardia after carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19700091" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Predictors of clinically significant postprocedural hypotension after carotid endarterectomy and carotid angioplasty with stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19233880" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Arterial pressure management and carotid endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23380550" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Antiplatelet therapy in endovascular surgery: the RENDOVASC study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27894896" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Systematic Review and Meta-analysis of Dual Versus Single Antiplatelet Therapy in Carotid Interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16565792" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15966092" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The benefits of combined anti-platelet treatment in carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27241270" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36328140" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Periprocedural P2Y12 inhibitors improve perioperative outcomes after carotid stenting by primarily decreasing strokes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26717867" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35598721" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282494" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23490041" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23138609" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26620397" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25240903" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Statins reduce peri-procedural complications in carotid stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29914834" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Statins reduce mortality and failure to rescue after carotid artery stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29100876" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Preoperative Antiplatelet and Statin Use Does Not Affect Outcomes after Carotid Endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30101624" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28626049" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23088806" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The effect of statin use on embolic potential during carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28045242" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Evidence for periprocedural antiplatelet therapy, heparinization and bridging of coumarin therapy in carotid revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27541652" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26203535" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Safety of Uninterrupted Warfarin Therapy in Patients Undergoing Cardiovascular Endovascular Procedures: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22036124" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of perioperative bridging heparin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29937033" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27645027" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Acute Carotid Stent Thrombosis: A Comprehensive Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17050890" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19268766" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Intracranial hemorrhage after carotid endarterectomy and carotid stenting in the United States in 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15120817" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting: risk factors, prevention, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24357658" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Non-ST-elevation myocardial infarction in patients undergoing carotid endarterectomy or carotid artery stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8751840" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8798126" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Stenting in the carotid artery: initial experience in 110 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11039360" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Abciximab rescue in acute carotid stent thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11692038" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Carotid stent thrombosis: report of 2 fatal cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16717230" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Late in-stent thrombosis following carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29861139" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9313696" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Recurrent carotid stenosis after carotid endarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12932179" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Healing of carotid stents: a prospective duplex ultrasound study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22857850" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15625299" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Systematic review of early recurrent stenosis after carotid angioplasty and stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445358" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9756575" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Recurrent carotid stenosis : results of the asymptomatic carotid atherosclerosis study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15653582" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Restenosis after carotid angioplasty, stenting, or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433952" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Comparison of open and endovascular treatments of post-carotid endarterectomy restenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27328701" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Predictors of Restenosis Following Carotid Angioplasty and Stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403765" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Long-term results of carotid stenting versus endarterectomy in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15768001" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Long-term results of carotid stenting are competitive with surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440186" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Stenting for carotid artery stenosis: fractures, proposed etiology and the need for surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28982691" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Carotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
